FALCO HOLDINGS Co., Ltd (JP:4671)
:4671
Want to see JP:4671 full AI Analyst Report?
Top Page
FALCO HOLDINGS Co., Ltd
(4671)
Select Model
Select Model
Rating:71Outperform
Price Target:
¥2,936.00
▲(9.51% Upside)
Action:Upgraded
Date:05/14/26
The score is primarily supported by strong financial stability (very low leverage) and attractive valuation (moderate P/E and high dividend yield). Offsetting these positives, technical indicators show weak momentum with oversold signals, and operating performance remains only moderate versus prior peak profitability.
Positive Factors
Balance Sheet Strength
Very low and improving leverage provides durable financial flexibility. With minimal debt burden the company can fund operations, capex, dividends or opportunistic M&A without heavy refinancing risk, increasing resilience through cyclical healthcare demand shifts.
Negative Factors
Uneven Revenue Growth
Revenue recovery has been uneven following prior declines, indicating limited momentum and potential dependence on cyclical or one-off drivers. Persistent modest top-line growth constrains scale advantages and makes long-term earnings expansion more uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Very low and improving leverage provides durable financial flexibility. With minimal debt burden the company can fund operations, capex, dividends or opportunistic M&A without heavy refinancing risk, increasing resilience through cyclical healthcare demand shifts.
Read all positive factors
FALCO HOLDINGS Co., Ltd (4671) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥25.43B
Dividend Yield4.81%
Average Volume (3M)15.38K
Price to Earnings (P/E)13.0
Beta (1Y)0.58
Revenue Growth0.61%
EPS Growth10.66%
CountryJP
Employees1,117
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)188.97
Shares Outstanding10,680,177
10 Day Avg. Volume10,950
30 Day Avg. Volume15,383
Financial Highlights & Ratios
PEG Ratio1.23
Price to Book (P/B)1.01
Price to Sales (P/S)0.60
P/FCF Ratio17.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)182.7
Revenue Forecast (FY)¥43.60B
FALCO HOLDINGS Co., Ltd Business Overview & Revenue Model
Company Description
FALCO HOLDINGS Co., Ltd., a medical service company, primarily provides clinical testing and dispensing pharmacy services to medical institutions and companies in Japan. It offers clinical testing services in the fields of genetic tests, biochemis...
How the Company Makes Money
FALCO HOLDINGS Co., Ltd. generates revenue mainly through its clinical testing services for hospitals, clinics, and other healthcare organizations. It also earns income from diagnostic services related to patient health assessments and drug develo...
FALCO HOLDINGS Co., Ltd Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
86
Very Positive
Cash Flow
68
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 43.52B | 43.58B | 43.31B | 43.01B | 46.91B | 50.01B |
| Gross Profit | 13.57B | 13.81B | 13.35B | 12.92B | 14.64B | 17.32B |
| EBITDA | 3.83B | 3.56B | 3.72B | 3.56B | 4.75B | 6.55B |
| Net Income | 1.98B | 2.02B | 1.92B | 1.67B | 2.26B | 3.53B |
Balance Sheet | ||||||
| Total Assets | 36.75B | 36.86B | 36.02B | 36.42B | 38.89B | 40.26B |
| Cash, Cash Equivalents and Short-Term Investments | 9.32B | 9.27B | 9.42B | 10.06B | 12.60B | 10.64B |
| Total Debt | 1.24B | 1.25B | 1.44B | 817.00M | 2.80B | 4.07B |
| Total Liabilities | 12.21B | 10.99B | 10.76B | 10.40B | 12.30B | 16.77B |
| Stockholders Equity | 24.54B | 25.87B | 25.25B | 26.03B | 26.59B | 23.48B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.54B | 1.54B | 2.19B | 708.00M | 1.94B |
| Operating Cash Flow | 0.00 | 2.88B | 2.62B | 3.43B | 2.09B | 4.13B |
| Investing Cash Flow | 0.00 | -2.03B | -1.18B | -1.45B | 322.00M | -2.69B |
| Financing Cash Flow | 0.00 | -2.00B | -2.08B | -4.53B | -448.00M | -2.41B |
FALCO HOLDINGS Co., Ltd Technical Analysis
Neutral
2681.00
Price Trends
2614.57
Negative
2594.92
Positive
2482.07
Positive
Market Momentum
1.98
Positive
47.88
Neutral
29.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4671, the sentiment is Neutral. The current price of 2681 is above the 20-day moving average (MA) of 2611.13, above the 50-day MA of 2614.57, and above the 200-day MA of 2482.07, indicating a neutral trend. The MACD of 1.98 indicates Positive momentum. The RSI at 47.88 is Neutral, neither overbought nor oversold. The STOCH value of 29.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4671.
FALCO HOLDINGS Co., Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥25.43B | 12.98 | ― | 4.81% | 0.61% | 10.66% | |
63 Neutral | ¥131.82B | 19.87 | 5.94% | 3.34% | 4.94% | 26.92% | |
54 Neutral | ¥17.46B | 7.05 | ― | ― | 28.07% | ― | |
53 Neutral | ¥50.79B | 12.89 | ― | 2.79% | 0.34% | -7.27% | |
52 Neutral | ¥18.25B | 10.03 | ― | 3.71% | 2.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥20.22B | -5.20 | -184.71% | ― | 29.94% | 86.03% |
* Healthcare Sector Average
JP:4671
FALCO HOLDINGS Co., Ltd
2,587.00
401.14
18.35%
JP:4563
AnGes
50.00
-15.00
-23.08%
JP:4694
BML
3,525.00
683.46
24.05%
JP:2395
Shin Nippon Biomedical Laboratories, Ltd.
1,220.00
-33.80
-2.70%
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,080.00
-101.16
-4.64%
JP:4579
RaQualia Pharma Inc.
714.00
184.00
34.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.